Plasma soluble vascular endothelial growth factor receptor-1 concentration is elevated prior to the clinical diagnosis of pre-eclampsia.

A longitudinal study of angiogenic (placental growth factor) and anti-angiogenic (soluble endoglin and soluble vascular endothelial growth factor receptor-1) factors in normal pregnancy and patients destined to develop preeclampsia and deliver a small for gestational age neonate. J Matern Fetal Neonatal Med (2008) 3.39

Preeclampsia, a disease of the maternal endothelium: the role of antiangiogenic factors and implications for later cardiovascular disease. Circulation (2011) 2.55

Autoantibody from women with preeclampsia induces soluble Fms-like tyrosine kinase-1 production via angiotensin type 1 receptor and calcineurin/nuclear factor of activated T-cells signaling. Hypertension (2008) 2.42

Clinical characterization and outcomes of preeclampsia with normal angiogenic profile. Hypertens Pregnancy (2013) 2.22

The "Great Obstetrical Syndromes" are associated with disorders of deep placentation. Am J Obstet Gynecol (2010) 1.99

Molecular mechanisms of preeclampsia. Microvasc Res (2007) 1.90

Angiogenic factors and the risk of adverse outcomes in women with suspected preeclampsia. Circulation (2012) 1.88

Transcriptionally active syncytial aggregates in the maternal circulation may contribute to circulating soluble fms-like tyrosine kinase 1 in preeclampsia. Hypertension (2012) 1.86

A prospective cohort study of the value of maternal plasma concentrations of angiogenic and anti-angiogenic factors in early pregnancy and midtrimester in the identification of patients destined to develop preeclampsia. J Matern Fetal Neonatal Med (2009) 1.84

The change in concentrations of angiogenic and anti-angiogenic factors in maternal plasma between the first and second trimesters in risk assessment for the subsequent development of preeclampsia and small-for-gestational age. J Matern Fetal Neonatal Med (2008) 1.60

Identification of patients at risk for early onset and/or severe preeclampsia with the use of uterine artery Doppler velocimetry and placental growth factor. Am J Obstet Gynecol (2007) 1.47

Potential markers of preeclampsia--a review. Reprod Biol Endocrinol (2009) 1.44

Potential roles of angiotensin receptor-activating autoantibody in the pathophysiology of preeclampsia. Hypertension (2007) 1.37

Reduction of circulating soluble Flt-1 alleviates preeclampsia-like symptoms in a mouse model. J Cell Mol Med (2009) 1.24

A brief overview of preeclampsia. J Clin Med Res (2013) 1.23

A comprehensive review of hypertension in pregnancy. J Pregnancy (2012) 1.16

Preeclampsia-related inflammatory cytokines regulate interleukin-6 expression in human decidual cells. Am J Pathol (2008) 1.14

Maternal plasma concentrations of angiogenic/anti-angiogenic factors are of prognostic value in patients presenting to the obstetrical triage area with the suspicion of preeclampsia. J Matern Fetal Neonatal Med (2011) 1.13

Angiogenic factors in diagnosis, management, and research in preeclampsia. Hypertension (2013) 1.11

Is inflammation the cause of pre-eclampsia? Biochem Soc Trans (2011) 1.09

A subset of patients destined to develop spontaneous preterm labor has an abnormal angiogenic/anti-angiogenic profile in maternal plasma: evidence in support of pathophysiologic heterogeneity of preterm labor derived from a longitudinal study. J Matern Fetal Neonatal Med (2009) 1.09

First-trimester maternal serum PP13 in the risk assessment for preeclampsia. Am J Obstet Gynecol (2008) 1.08

Late-onset preeclampsia is associated with an imbalance of angiogenic and anti-angiogenic factors in patients with and without placental lesions consistent with maternal underperfusion. J Matern Fetal Neonatal Med (2011) 1.07

Maternal plasma concentrations of angiogenic/antiangiogenic factors in the third trimester of pregnancy to identify the patient at risk for stillbirth at or near term and severe late preeclampsia. Am J Obstet Gynecol (2013) 1.05

Angiotensin receptors, autoimmunity, and preeclampsia. J Immunol (2007) 1.03

The use of angiogenic biomarkers to differentiate non-HELLP related thrombocytopenia from HELLP syndrome. J Matern Fetal Neonatal Med (2010) 1.03

Placental lesions associated with maternal underperfusion are more frequent in early-onset than in late-onset preeclampsia. J Perinat Med (2011) 1.01

Circulating angiogenic factors and risk of adverse maternal and perinatal outcomes in twin pregnancies with suspected preeclampsia. Hypertension (2012) 0.97

New developments in the pathogenesis of preeclampsia. Adv Chronic Kidney Dis (2013) 0.97

An imbalance between angiogenic and anti-angiogenic factors precedes fetal death in a subset of patients: results of a longitudinal study. J Matern Fetal Neonatal Med (2010) 0.95

Plasma concentrations of soluble endoglin versus standard evaluation in patients with suspected preeclampsia. PLoS One (2012) 0.94

Circulating soluble endoglin and placental abruption. Prenat Diagn (2008) 0.93

Preeclampsia and the Anti-Angiogenic State. Pregnancy Hypertens (2011) 0.92

Twin-to-twin transfusion syndrome: an antiangiogenic state? Am J Obstet Gynecol (2008) 0.92

Maternal serum adiponectin multimers in preeclampsia. J Perinat Med (2009) 0.92

Preeclampsia and small-for-gestational age are associated with decreased concentrations of a factor involved in angiogenesis: soluble Tie-2. J Matern Fetal Neonatal Med (2008) 0.92

Microbial invasion of the amniotic cavity in preeclampsia as assessed by cultivation and sequence-based methods. J Perinat Med (2010) 0.92

Severe preeclampsia is characterized by increased placental expression of galectin-1. J Matern Fetal Neonatal Med (2008) 0.91

Placental growth hormone is increased in the maternal and fetal serum of patients with preeclampsia. J Matern Fetal Neonatal Med (2007) 0.91

Preeclampsia and pregnancies with small-for-gestational age neonates have different profiles of complement split products. J Matern Fetal Neonatal Med (2010) 0.88

Implementation of the sFlt-1/PlGF ratio for prediction and diagnosis of pre-eclampsia in singleton pregnancy: implications for clinical practice. Ultrasound Obstet Gynecol (2015) 0.88

Circulating angiogenic and antiangiogenic factors in women with eclampsia. Am J Obstet Gynecol (2010) 0.88

Pre-eclampsia: its pathogenesis and pathophysiolgy. Cardiovasc J Afr (2016) 0.88

Cost and resource implications with serum angiogenic factor estimation in the triage of pre-eclampsia. BJOG (2013) 0.88

Circulating angiogenic factors in gestational proteinuria without hypertension. Am J Obstet Gynecol (2009) 0.88

Evidence of an imbalance of angiogenic/antiangiogenic factors in massive perivillous fibrin deposition (maternal floor infarction): a placental lesion associated with recurrent miscarriage and fetal death. Am J Obstet Gynecol (2013) 0.87

Retinol binding protein 4--a novel association with early-onset preeclampsia. J Perinat Med (2010) 0.87

Placental Protein 13 (PP13) - A Placental Immunoregulatory Galectin Protecting Pregnancy. Front Immunol (2014) 0.87

Angiogenic factors and natural killer (NK) cells in the pathogenesis of preeclampsia. J Reprod Immunol (2007) 0.87

Plasma concentrations of angiogenic/anti-angiogenic factors have prognostic value in women presenting with suspected preeclampsia to the obstetrical triage area: a prospective study. J Matern Fetal Neonatal Med (2013) 0.87

Maternal serum soluble CD30 is increased in normal pregnancy, but decreased in preeclampsia and small for gestational age pregnancies. J Matern Fetal Neonatal Med (2007) 0.86

Tissue factor and its natural inhibitor in pre-eclampsia and SGA. J Matern Fetal Neonatal Med (2008) 0.86

Thrombin regulates soluble fms-like tyrosine kinase-1 (sFlt-1) expression in first trimester decidua: implications for preeclampsia. Am J Pathol (2007) 0.86

Plasma soluble endoglin concentration in pre-eclampsia is associated with an increased impedance to flow in the maternal and fetal circulations. Ultrasound Obstet Gynecol (2010) 0.86

The therapeutic potential of antioxidants, ER chaperones, NO and H2S donors, and statins for treatment of preeclampsia. Front Pharmacol (2014) 0.85

Unexplained fetal death is associated with increased concentrations of anti-angiogenic factors in amniotic fluid. J Matern Fetal Neonatal Med (2010) 0.85

Pravastatin to prevent recurrent fetal death in massive perivillous fibrin deposition of the placenta (MPFD). J Matern Fetal Neonatal Med (2015) 0.85

A decrease in maternal plasma concentrations of sVEGFR-2 precedes the clinical diagnosis of preeclampsia. Am J Obstet Gynecol (2010) 0.85

Evolutionary origins of the placental expression of chromosome 19 cluster galectins and their complex dysregulation in preeclampsia. Placenta (2014) 0.84

Serum and plasma determination of angiogenic and anti-angiogenic factors yield different results: the need for standardization in clinical practice. J Matern Fetal Neonatal Med (2010) 0.83

Levels of soluble fms-like tyrosine kinase one in first trimester and outcomes of pregnancy: a systematic review. Reprod Biol Endocrinol (2011) 0.83

An Elevated Maternal Plasma Soluble fms-Like Tyrosine Kinase-1 to Placental Growth Factor Ratio at Midtrimester Is a Useful Predictor for Preeclampsia. Obstet Gynecol Int (2013) 0.83

Circulating anti-angiogenic factors during hypertensive pregnancy and increased risk of respiratory distress syndrome in preterm neonates. J Matern Fetal Neonatal Med (2011) 0.82

Evidence in support of a role for anti-angiogenic factors in preterm prelabor rupture of membranes. J Matern Fetal Neonatal Med (2010) 0.82

Preeclampsia - Aetiology, Current Diagnostics and Clinical Management, New Therapy Options and Future Perspectives. Geburtshilfe Frauenheilkd (2012) 0.81

Acute pyelonephritis during pregnancy changes the balance of angiogenic and anti-angiogenic factors in maternal plasma. J Matern Fetal Neonatal Med (2010) 0.81

In vivo experiments reveal the good, the bad and the ugly faces of sFlt-1 in pregnancy. PLoS One (2014) 0.80

Soluble fms-like tyrosine kinase 1 promotes angiotensin II sensitivity in preeclampsia. J Clin Invest (2016) 0.80

Systematic Review of Micro-RNA Expression in Pre-Eclampsia Identifies a Number of Common Pathways Associated with the Disease. PLoS One (2016) 0.79

Could alterations in maternal plasma visfatin concentration participate in the phenotype definition of preeclampsia and SGA? J Matern Fetal Neonatal Med (2010) 0.79

Maternal plasma soluble TRAIL is decreased in preeclampsia. J Matern Fetal Neonatal Med (2013) 0.79

Renal evaluation in women with preeclampsia. Nephron Extra (2012) 0.79

Angiogenic factors in preeclampsia: potential for diagnosis and treatment. Curr Opin Nephrol Hypertens (2013) 0.79

Full-length human placental sFlt-1-e15a isoform induces distinct maternal phenotypes of preeclampsia in mice. PLoS One (2015) 0.78

Molecular Mechanisms of Preeclampsia. Cold Spring Harb Perspect Med (2015) 0.78

Changes of placental syndecan-1 expression in preeclampsia and HELLP syndrome. Virchows Arch (2013) 0.78

Inflammatory biomarkers and spontaneous preterm birth among obese women. J Matern Fetal Neonatal Med (2015) 0.77

Maternal and neonatal circulating visfatin concentrations in patients with pre-eclampsia and a small-for-gestational age neonate. J Matern Fetal Neonatal Med (2010) 0.77

Detection and confirmation of serum lipid biomarkers for preeclampsia using direct infusion mass spectrometry. J Lipid Res (2016) 0.75

Circulating levels of neutrophil gelatinase-associated lipocalin (NGAL) correlate with the presence and severity of preeclampsia. Reprod Sci (2013) 0.75

Resveratrol inhibits proteinase-activated receptor-2-induced release of soluble vascular endothelial growth factor receptor-1 from human endothelial cells. EXCLI J (2013) 0.75

The effect of Silymarin on VEGF, VEGFR-1 and IL-1α levels in placental cultures of severe preeclamptic women. J Turk Ger Gynecol Assoc (2014) 0.75

Circulating Vascular Growth Factor (VEGF) Angiopoietin-1 (Angi-1) and Soluble Tie-2 Receptor in Pregnancy Complicated with Pre-eclampsia: A Prospective Study. J Obstet Gynaecol India (2013) 0.75

Comparison of thyroid hormone levels between normal and preeclamptic pregnancies. Med J Islam Repub Iran (2014) 0.75

Pathophysiology of preeclampsia: an angiogenic imbalance and long-lasting systemic vascular dysfunction. Hypertens Res (2016) 0.75

The prediction of late-onset preeclampsia: Results from a longitudinal proteomics study. PLoS One (2017) 0.75

Impact of Preeclampsia on Clinical and Functional Outcomes in Women With Peripartum Cardiomyopathy. Circ Heart Fail (2017) 0.75

Human placental growth hormone in normal and abnormal fetal growth. Biomed Rep (2017) 0.75

Maternal plasma soluble ST2 concentrations are elevated prior to the development of early and late onset preeclampsia - a longitudinal study. J Matern Fetal Neonatal Med (2017) 0.75

Epidemiology and causes of preterm birth. Lancet (2008) 18.96

Soluble endoglin and other circulating antiangiogenic factors in preeclampsia. N Engl J Med (2006) 7.06

A systems biology approach for pathway level analysis. Genome Res (2007) 6.95

Soluble endoglin contributes to the pathogenesis of preeclampsia. Nat Med (2006) 6.21

A novel signaling pathway impact analysis. Bioinformatics (2008) 5.06

Biological variation in HbA1c predicts risk of retinopathy and nephropathy in type 1 diabetes. Diabetes Care (2004) 3.59

The role of inflammation and infection in preterm birth. Semin Reprod Med (2007) 3.57

Dendrimer-based postnatal therapy for neuroinflammation and cerebral palsy in a rabbit model. Sci Transl Med (2012) 3.43

A longitudinal study of angiogenic (placental growth factor) and anti-angiogenic (soluble endoglin and soluble vascular endothelial growth factor receptor-1) factors in normal pregnancy and patients destined to develop preeclampsia and deliver a small for gestational age neonate. J Matern Fetal Neonatal Med (2008) 3.39

Microbial prevalence, diversity and abundance in amniotic fluid during preterm labor: a molecular and culture-based investigation. PLoS One (2008) 3.01

Primary, secondary, and tertiary interventions to reduce the morbidity and mortality of preterm birth. Lancet (2008) 2.90

Distinct subsets of microRNAs are expressed differentially in the human placentas of patients with preeclampsia. Am J Obstet Gynecol (2007) 2.78

Inflammation in preterm and term labour and delivery. Semin Fetal Neonatal Med (2006) 2.59

Machine learning and its applications to biology. PLoS Comput Biol (2007) 2.57

Failure of physiologic transformation of the spiral arteries in patients with preterm labor and intact membranes. Am J Obstet Gynecol (2003) 2.55

High and low hemoglobin glycation phenotypes in type 1 diabetes: a challenge for interpretation of glycemic control. J Diabetes Complications (2002) 2.42

Intrauterine infection and prematurity. Ment Retard Dev Disabil Res Rev (2002) 2.42

The fetal inflammatory response syndrome. Clin Obstet Gynecol (2007) 2.36

Listeriosis in human pregnancy: a systematic review. J Perinat Med (2011) 2.20

The role of cervical cerclage in obstetric practice: can the patient who could benefit from this procedure be identified? Am J Obstet Gynecol (2006) 2.11

The "Great Obstetrical Syndromes" are associated with disorders of deep placentation. Am J Obstet Gynecol (2010) 1.99

Evolution of the mammalian placenta revealed by phylogenetic analysis. Proc Natl Acad Sci U S A (2006) 1.89

Genomics, biogeography, and the diversification of placental mammals. Proc Natl Acad Sci U S A (2007) 1.86

A prospective cohort study of the value of maternal plasma concentrations of angiogenic and anti-angiogenic factors in early pregnancy and midtrimester in the identification of patients destined to develop preeclampsia. J Matern Fetal Neonatal Med (2009) 1.84

A sonographic short cervix as the only clinical manifestation of intra-amniotic infection. J Perinat Med (2006) 1.82

Evidence supporting a role for blockade of the vascular endothelial growth factor system in the pathophysiology of preeclampsia. Young Investigator Award. Am J Obstet Gynecol (2004) 1.81

Infection and prematurity and the role of preventive strategies. Semin Neonatol (2002) 1.78

Metabolomics in premature labor: a novel approach to identify patients at risk for preterm delivery. J Matern Fetal Neonatal Med (2010) 1.77

Universal cervical length screening and treatment with vaginal progesterone to prevent preterm birth: a decision and economic analysis. Am J Obstet Gynecol (2010) 1.77

Antenatal magnesium sulfate for the prevention of cerebral palsy in preterm infants less than 34 weeks' gestation: a systematic review and metaanalysis. Am J Obstet Gynecol (2009) 1.77

Identification of fetal and maternal single nucleotide polymorphisms in candidate genes that predispose to spontaneous preterm labor with intact membranes. Am J Obstet Gynecol (2010) 1.75

Smoking in pregnancy revisited: findings from a large population-based study. Am J Obstet Gynecol (2005) 1.75

Prevalence and diversity of microbes in the amniotic fluid, the fetal inflammatory response, and pregnancy outcome in women with preterm pre-labor rupture of membranes. Am J Reprod Immunol (2010) 1.74

Human spontaneous labor without histologic chorioamnionitis is characterized by an acute inflammation gene expression signature. Am J Obstet Gynecol (2006) 1.73

Maternal anemia during pregnancy is an independent risk factor for low birthweight and preterm delivery. Eur J Obstet Gynecol Reprod Biol (2005) 1.71

Treatment of abnormal vaginal flora in early pregnancy with clindamycin for the prevention of spontaneous preterm birth: a systematic review and metaanalysis. Am J Obstet Gynecol (2011) 1.69

Gene-centric genomewide association study via entropy. Genetics (2008) 1.68

Nifedipine in the management of preterm labor: a systematic review and metaanalysis. Am J Obstet Gynecol (2011) 1.65

Divergent trophoblast responses to bacterial products mediated by TLRs. J Immunol (2004) 1.64

A short cervix in women with preterm labor and intact membranes: a risk factor for microbial invasion of the amniotic cavity. Am J Obstet Gynecol (2005) 1.64

Antibiotic administration to patients with preterm premature rupture of membranes does not eradicate intra-amniotic infection. J Matern Fetal Neonatal Med (2007) 1.62

Clinical significance of intra-amniotic inflammation in patients with preterm premature rupture of membranes. Am J Obstet Gynecol (2004) 1.60

The change in concentrations of angiogenic and anti-angiogenic factors in maternal plasma between the first and second trimesters in risk assessment for the subsequent development of preeclampsia and small-for-gestational age. J Matern Fetal Neonatal Med (2008) 1.60

Intrauterine endotoxin administration leads to white matter diffusivity changes in newborn rabbits. J Child Neurol (2009) 1.58

Failure of physiologic transformation of the spiral arteries in the placental bed in preterm premature rupture of membranes. Am J Obstet Gynecol (2002) 1.58

Structural and functional comparison of mast cells in the pregnant versus nonpregnant human uterus. Am J Obstet Gynecol (2006) 1.54

The clinical significance of a positive Amnisure test in women with term labor with intact membranes. J Matern Fetal Neonatal Med (2009) 1.54

A systematic approach to the use of the multiplanar display in evaluation of abnormal vascular connections to the fetal heart using 4-dimensional ultrasonography. J Ultrasound Med (2007) 1.53

Analysis of microarray experiments of gene expression profiling. Am J Obstet Gynecol (2006) 1.53

Macrophages and apoptotic cell clearance during pregnancy. Am J Reprod Immunol (2004) 1.51

Amniotic fluid embolism: an evidence-based review. Am J Obstet Gynecol (2009) 1.50

The evolution of menstruation: a new model for genetic assimilation: explaining molecular origins of maternal responses to fetal invasiveness. Bioessays (2011) 1.50

The maternal plasma soluble vascular endothelial growth factor receptor-1 concentration is elevated in SGA and the magnitude of the increase relates to Doppler abnormalities in the maternal and fetal circulation. J Matern Fetal Neonatal Med (2008) 1.50

Toll-like receptor-2 and -4 in the chorioamniotic membranes in spontaneous labor at term and in preterm parturition that are associated with chorioamnionitis. Am J Obstet Gynecol (2004) 1.49

The prognosis of pregnancy conceived despite the presence of an intrauterine device (IUD). J Perinat Med (2010) 1.48

Identification of patients at risk for early onset and/or severe preeclampsia with the use of uterine artery Doppler velocimetry and placental growth factor. Am J Obstet Gynecol (2007) 1.47

The risk of impending preterm delivery in asymptomatic patients with a nonmeasurable cervical length in the second trimester. Am J Obstet Gynecol (2010) 1.45

Labour before a Caesarean section and the morphology of the lower uterine segment in the next pregnancy. J Obstet Gynaecol Can (2011) 1.45

Single- versus double-layer closure of the hysterotomy incision during cesarean delivery and risk of uterine rupture. Int J Gynaecol Obstet (2011) 1.45

A single nucleotide polymorphism in the matrix metalloproteinase-1 (MMP-1) promoter influences amnion cell MMP-1 expression and risk for preterm premature rupture of the fetal membranes. J Biol Chem (2001) 1.42

A comparison of gene set analysis methods in terms of sensitivity, prioritization and specificity. PLoS One (2013) 1.41